PRESERVE trial confirms low risk for most inferior vena cava filters, but benefit remains uncertain
- PMID: 37080687
- PMCID: PMC12245421
- DOI: 10.1016/j.jvsv.2023.01.001
PRESERVE trial confirms low risk for most inferior vena cava filters, but benefit remains uncertain
Comment on
-
Predicting the Safety and Effectiveness of Inferior Vena Cava Filters (PRESERVE): Outcomes at 12 months.J Vasc Surg Venous Lymphat Disord. 2023 May;11(3):573-585.e6. doi: 10.1016/j.jvsv.2022.11.002. Epub 2023 Feb 23. J Vasc Surg Venous Lymphat Disord. 2023. PMID: 36872169
References
-
- Johnson M.S., Spies J.B., Scott K.T., Kato B.S., Mu X., Rectenwald J.E., et al. Predicting the safety and effectiveness of inferior vena cava filters (PRESERVE): outcomes at 12 months. J Vasc Surg Venous Lymphatic Disord. 2023;11:573–585. - PubMed
-
- Kaufman J.A., Barnes G.D., Chaer R.A., Cuschieri J., Eberhardt R.T., Johnson M.S., et al. Society of Interventional Radiology clinical practice guideline for inferior vena cava filters in the treatment of patients with venous thromboembolic disease: developed in collaboration with the American College of Cardiology, American College of Chest physicians, American College of Surgeons Committee on Trauma, American Heart Association, Society for Vascular Surgery, and Society for Vascular Medicine. J Vasc Interv Radiol. 2020;31:1529–1544. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical